Key result
Prasugrel shows no benefit over clopidogrel for major vascular events in high-risk thrombotic stroke patients.
Why the study?
The efficacy and safety of prasugrel compared with clopidogrel in thrombotic stroke patients at risk of ischemic stroke recurrence remained to be examined.
Does prasugrel reduce the composite incidence of ischemic stroke, MI, and vascular death compared to clopidogrel in thrombotic stroke patients at risk of ischemic stroke recurrence?
RCT (n=235)
Double-blind
Permuted block technique
Yes
Does prasugrel reduce the composite incidence of ischemic stroke, MI, and vascular death compared to clopidogrel in thrombotic stroke patients at risk of ischemic stroke recurrence?
In Japanese patients with thrombotic stroke and risk factors for recurrence, prasugrel 3.75 mg/day demonstrated comparable efficacy and safety to clopidogrel 75 mg/day.
Answers are grounded in this paper and cite their sources.
Offers clinicians an alternative antiplatelet option in high-risk thrombotic stroke; confirms comparable efficacy in this RCT population.
AIM: To examine the efficacy and safety of prasugrel vs clopidogrel in thrombotic stroke patients at risk of ischemic stroke. METHODS: This multicenter, active-controlled, randomized, double-blind, double-dummy, parallel group study enrolled thrombotic stroke patients aged ≥ 50 years at risk of ischemic stroke. Patients received prasugrel (3.75 mg/day) or clopidogrel (75 or 50 mg/day) for 24-48 weeks; other antiplatelet drugs were prohibited. The primary efficacy endpoint was the composite incidence of ischemic stroke, myocardial infarction (MI), and death from other vascular causes from the start to 1 day after treatment completion or discontinuation. Secondary efficacy endpoints included the incidences of ischemic stroke, MI, death from other vascular causes, ischemic stroke and transient ischemic attack, and stroke. Safety endpoints included bleeding events and adverse events (AEs). RESULTS: In the prasugrel (N=118) and clopidogrel (N=112; all received 75 mg) groups, the primary efficacy endpoint composite incidence (95% confidence interval) was 6.8% (3.0%-12.9%) and 7.1% (3.1%-13.6%), respectively. The risk ratio (prasugrel/clopidogrel) was 0.949 (0.369-2.443). Secondary efficacy endpoints followed a similar trend. The combined incidences of life-threatening, major, and clinically relevant bleeding were 5.0% and 3.5% in the prasugrel and clopidogrel groups, respectively. The incidences of all bleeding events and AEs were 19.2% and 24.6% and 76.7% and 82.5% in the prasugrel and clopidogrel groups, respectively. No serious AEs were causally related to prasugrel. CONCLUSIONS: We observed a risk reduction of 5% with prasugrel vs clopidogrel, indicating comparable efficacy. There were no major safety issues for prasugrel.
No takes yet. Share an insight, caveat, or question.
Kitazono et al. (2022) conducted an RCT in Thrombotic stroke with risk factors for ischemic stroke recurrence (n=235). Prasugrel vs. Clopidogrel 75 mg/day or 50 mg/day was evaluated on Composite incidence of ischemic stroke, myocardial infarction, and death from other vascular causes (RR 0.949, 95% CI 0.369-2.443). Prasugrel showed comparable efficacy to clopidogrel in reducing the composite of ischemic stroke, myocardial infarction, and vascular death in thrombotic stroke patients at high risk of recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: